naphtalina/iStock via Getty Images
NovoCure (NASDAQ:NVCR) shares rose on Tuesday to approach a three-month high after Wells Fargo upgraded the stock to Overweight from Equal Weight citing a positive Phase 3 readout for the company’s Tumor Treating Fields (TTFields) therapy next month.
The decision comes as the Saint Helier, Jersey-based firm is set to present results from its Phase 3 LUNAR study for TTFields as a late-line option in metastatic, non-small cell lung cancer (NSCLC) on June 6 at a leading cancer-focused medical conference.
Wells Fargo analyst Lawrence Biegelsen projects upside to the stock in the event of a “sufficiently clean” LUNAR readout that could back approval for TTFields as a second-line option.
“While a 1L study will take time (we assume 2030 US launch), the significant TAM [total addressable market] in 1L boosts our DCF analysis,” the analyst wrote, highlighting the potential of TTFields as a first-line option.
Biegelsen, who raised his price target on NVCR to $104 from $70, projects a 60% chance of good second-line data backing a first-line move compared to a 40% chance of a mixed second-line readout.
More on NovoCure
- Novocure’s brain cancer treatment Optune gets reimbursement in France
- NovoCure: Pipeline Conversion Is Key